Natixis Advisors LLC acquired a new position in Fresenius Medical Care AG (NYSE:FMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 14,667 shares of the company's stock, valued at approximately $332,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FMS. Callan Family Office LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at about $502,000. Callan Capital LLC acquired a new stake in shares of Fresenius Medical Care during the fourth quarter worth $297,000. Sanctuary Advisors LLC purchased a new stake in Fresenius Medical Care during the 4th quarter valued at about $983,000. ABC Arbitrage SA acquired a new position in Fresenius Medical Care in the 4th quarter worth approximately $4,215,000. Finally, Verition Fund Management LLC purchased a new position in Fresenius Medical Care during the 3rd quarter worth approximately $237,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. Truist Financial increased their price objective on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. StockNews.com raised Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a research note on Monday, December 2nd.
Read Our Latest Stock Analysis on Fresenius Medical Care
Fresenius Medical Care Stock Performance
NYSE FMS traded up $0.16 during mid-day trading on Monday, reaching $24.94. 400,572 shares of the stock were exchanged, compared to its average volume of 313,371. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $25.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The business's 50 day moving average is $24.06 and its 200-day moving average is $22.57. The company has a market capitalization of $14.64 billion, a P/E ratio of 20.61, a P/E/G ratio of 0.76 and a beta of 0.99.
Fresenius Medical Care Company Profile
(
Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
